Northeastern University engineering professor Jeffrey Ruberti and his research colleagues are breaking new ground in the technique known as "hybrid tissue engineering" by attempting to control the behavior of human cells such that they can be induced to produce corneas for human transplant.  An important part of their research has been conducted with a state-of-the-art bioreactor that was developed by Professor Ruberti’s group and commercialized by ADMET, Inc of Norwood, MA.